Join
Live feed
·
INSIDERFilingvia Quantisnow
Crinetics Pharmaceuticals Inc. logo

Director Vivaldi Coelho Rogerio sold $120,000 worth of shares (3,000 units at $40.00) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 19,225 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
CRNX· Crinetics Pharmaceuticals Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CRNX (Crinetics Pharmaceuticals Inc.) and more on Quantisnow.